EU says Johnson & Johnson's deal for Takeda patch may harm competition

BRUSSELS (Reuters) - EU antitrust regulators have opened a full investigation into Johnson & Johnson's acquisition of Takeda Pharmaceutical's surgical patch product TachoSil, concerned that the deal could lead to reduced choice and higher prices for customers.Takeda, Japan's biggest drugmaker, announced the sale of TachoSil, a surgical patch for bleeding control, to U.S. giant Johnson & Johnson's subsidiary Ethicon for $400 million (342 million pounds) last May.The European Commission said a..